Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Boehringer Ingelheim
Harvard Business School
Colorcon
Mallinckrodt

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Favipiravir

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Favipiravir: Patents, clinical trial progress, indications

Favipiravir is an investigational drug.

There have been 8 clinical trials for Favipiravir. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.

The most common disease conditions in clinical trials are Influenza, Human, Hemorrhagic Fever, Ebola, and Virus Diseases. The leading clinical trial sponsors are MDVI, LLC, Institut National de la Santé Et de la Recherche Médicale, France, and MediVector, Inc.

There are fifteen US patents protecting this investigational drug and two hundred and eighty-six international patents.

Recent Clinical Trials for Favipiravir
TitleSponsorPhase
Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the SemenInstitut National de la Santé Et de la Recherche Médicale, FrancePhase 2
Efficacy of Favipiravir Against Ebola (JIKI)Institut National de la Santé Et de la Recherche Médicale, FrancePhase 2
Efficacy of Favipiravir Against Severe Ebola Virus Disease307 Hospital of PLAPhase 2

See all Favipiravir clinical trials

Clinical Trial Summary for Favipiravir

Top disease conditions for Favipiravir
Top clinical trial sponsors for Favipiravir

See all Favipiravir clinical trials

US Patents for Favipiravir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Favipiravir   Start Trial Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same Toyama Chemical Co., Ltd. (Tokyo, JP)   Start Trial
Favipiravir   Start Trial Pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof Toyama Chemical Co., Ltd. (Tokyo, JP)   Start Trial
Favipiravir   Start Trial Compositions and kits for treating influenza Adamas Pharmaceuticals, Inc. (Emeryville, CA)   Start Trial
Favipiravir   Start Trial Compositions and kits for treating influenza Adamas Pharmaceuticals, Inc. (Emeryville, CA)   Start Trial
Favipiravir   Start Trial Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same Toyama Chemical Co., Ltd. (Tokyo, JP)   Start Trial
Favipiravir   Start Trial Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide Toyama Chemical Co., Ltd. (Tokyo, JP)   Start Trial
Favipiravir   Start Trial Method for producing dichloropyrazine derivative Nippon Soda Co., Ltd. (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Favipiravir

Drugname Country Document Number Estimated Expiration Related US Patent
Favipiravir Austria 376418 2018-08-20   Start Trial
Favipiravir Australia 5300499 2018-08-20   Start Trial
Favipiravir Australia 756635 2018-08-20   Start Trial
Favipiravir Brazil 9913097 2018-08-20   Start Trial
Favipiravir Canada 2339272 2018-08-20   Start Trial
Favipiravir China 1154493 2018-08-20   Start Trial
Favipiravir China 1275947 2018-08-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Moodys
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.